The Citi analyst pointed out that despite the recent weak sentiment surrounding Apellis stocks, due to the European Union's non-approval of Syfovre and uncertainties regarding the strength of its U.S.

While Astellas’ Izervay and Apellis’ Syfovre battle for market share in geographic atrophy (GA) in the United States, both companies are struggling to reach patients in the indication in Europe.

Astellas confirmed today that it will withdraw its EMA filing for avacincaptad pegol as a treatment for eye disorder ...

The Citi analyst pointed out that despite the recent weak sentiment surrounding Apellis stocks, due to the European Union's non-approval of Syfovre and uncertainties regarding the strength of its ...

Add a description, image, and links to the molecule-driver topic page so that developers can more easily learn about it.

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly.

RBC Capital analyst Lisa Walter initiated coverage of Apellis (APLS) with a Sector Perform rating and $25 price target Complement inhibitors Syfovre and Izervay were approved for geographic ...

I just felt I could do so much more. And I really do credit NAD for it.” Camilla Thompson credits the NAD molecule for her improved functioning.Credit: Syl Marie NAD – Nicotinamide adenine ...